We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Addex Therapeutics Ltd | NASDAQ:ADXN | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.10 | 1.13% | 8.95 | 8.82 | 10.04 | 9.394 | 8.94 | 9.09 | 7,875 | 01:00:00 |
| PROSPECTUS | | | | | | | |
| | |
Page
|
| |||
| | | | ii | | | |
| | | | iii | | | |
| | | | 1 | | | |
| | | | 7 | | | |
| | | | 9 | | | |
| | | | 18 | | | |
| | | | 19 | | | |
| | | | 20 | | | |
| | | | 21 | | | |
| | | | 22 | | | |
| | | | 24 | | | |
| | | | 29 | | | |
| | | | 39 | | | |
| | | | 41 | | | |
| | | | 43 | | | |
| | | | 43 | | | |
| | | | 43 | | | |
| | | | 43 | | | |
| | | | 45 | | | |
| | | | 46 | | |
| | |
As of November 30, 2021
|
| |||||||||
CHF in thousands
|
| |
Actual
(unaudited) |
| |
As Adjusted
(unaudited) |
| ||||||
Cash and cash equivalents
|
| | | | 12,909 | | | | | | 20,614 | | |
Shareholders’ equity | | | | | | | | | | | | | |
Share capital
|
| | | | 49,273 | | | | | | 49,273 | | |
Share premium
|
| | | | 288,279 | | | | | | 287,419 | | |
Treasury shares reserve
|
| | | | (15,475) | | | | | | (11,722) | | |
Other reserves
|
| | | | 15,898 | | | | | | 20,711 | | |
Accumulated deficit
|
| | | | (327,567) | | | | | | (327,567) | | |
Total shareholders’ equity, net
|
| | | | 10,408 | | | | | | 18,114 | | |
Total capitalization
|
| | | | 10,408 | | | | | | 18,114 | | |
Number of shares
|
| |
Number of registered
shareholders on December 31, 2021 |
| |||
1 to 100
|
| | | | 228 | | |
101 to 1,000
|
| | | | 905 | | |
1,001 to 10,000
|
| | | | 1,068 | | |
10,001 to 100,000
|
| | | | 170 | | |
100,001 to 1,000,000
|
| | | | 10 | | |
1,000,001 to 10,000,000
|
| | | | 7 | | |
Shareholder structure by country
(weighted by number of shares) |
| | | | | | |
United States
|
| | | | 32.29% | | |
Switzerland
|
| | | | 48.89% | | |
Other
|
| | | | 1.11% | | |
Non identified
|
| | | | 17.71% | | |
Nominal share capital
|
| | | |
December 31, 2019
|
| |
CHF 32,848,635
|
|
December 31, 2020
|
| |
CHF 32,848,635
|
|
December 31, 2021
|
| |
CHF 49,272,952
|
|
Conditional share capital
|
| | | |
December 31, 2019
|
| |
CHF 16,424,317
|
|
December 31, 2020
|
| |
CHF 16,424,317
|
|
December 31, 2021
|
| |
CHF 24,636,476
|
|
Authorized share capital
|
| | | |
December 31, 2019
|
| |
CHF 16,424,317
|
|
December 31, 2020
|
| |
CHF 16,424,317
|
|
December 31, 2021
|
| |
CHF 24,636,476
|
|
|
Service
|
| |
Fee
|
|
|
•
Issuance of ADSs (e.g., an issuance of ADS upon a deposit of shares, upon a change in the ADS(s)-to- shares ratio, or for any other reason), excluding ADS issuances as a result of distributions of shares
|
| | Up to U.S. 5¢ per ADS issued | |
|
•
Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited property, upon a change in the ADS(s)-to-shares ratio, or for any other reason)
|
| | Up to U.S. 5¢ per ADS cancelled | |
|
•
Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements)
|
| | Up to U.S. 5¢ per ADS held | |
|
Service
|
| |
Fee
|
|
|
•
Distribution of ADSs pursuant to (i) stock dividends or other free stock distributions, or (i) exercise of rights to purchase additional ADSs
|
| | Up to U.S. 5¢ per ADS held | |
|
•
Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g., upon a spin-off)
|
| | Up to U.S. 5¢ per ADS held | |
|
•
ADS Services
|
| | Up to U.S. 5¢ per ADS held on the applicable record date(s) established by the depositary | |
|
•
Registration of ADS transfers (e.g., upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and vice versa, or for any other reason)
|
| | Up to U.S. 5¢ per ADS (or fraction thereof) transferred | |
|
•
Conversion of ADSs of one series for ADSs of another series (e.g., upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs (each as defined in the Deposit Agreement) into freely transferable ADSs, and vice versa).
|
| | Up to U.S. 5¢ per ADS (or fraction thereof) converted | |
2021
|
| |
Fixed
|
| |
Variable compensation
|
| | | | | | | ||||||||||||||||||
CHF
|
| |
cash
compensation |
| |
cash
attendance |
| |
number of
equity incentive units |
| |
value of
equity incentive units |
| |
Total
2021 |
| |||||||||||||||
Vincent Lawton, chairman..
|
| | | | 26,590 | | | | | | 26,590 | | | | | | 70,000 | | | | | | 54,129 | | | | |
|
107,309
|
| |
Raymond Hill, member
|
| | | | 15,954 | | | | | | 15,954 | | | | | | 40,000 | | | | | | 30,931 | | | | |
|
62,839
|
| |
Tim Dyer, member
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | |
|
—
|
| |
Roger Mills, member
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | |
|
—
|
| |
Jake Nunn, member
|
| | | | 13,295 | | | | | | 13,295 | | | | | | 30,000 | | | | | | 23,198 | | | | |
|
49,788
|
| |
Isaac Manke, member
|
| | | | 13,295 | | | | | | 13,295 | | | | | | 30,000 | | | | | | 23,198 | | | | |
|
49,788
|
| |
Total | | | | | 69,134 | | | | | | 69,134 | | | | | | 170,000 | | | | | | 131,456 | | | | | | 269,724 | | |
2021
|
| |
Fixed
|
| |
Variable compensation
|
| | | | | | | ||||||||||||||||||
CHF
|
| |
cash
compensation |
| |
Cash
|
| |
number of
equity incentive units |
| |
value of
shares |
| |
Total
2021 |
| |||||||||||||||
Total Executive Management
|
| | | | 1,082,184 | | | | | | 395,316 | | | | | | 1,438,065 | | | | | | 1,186,493 | | | | | | 2,663,993 | | |
|
SEC registration fee
|
| | | $ | 1,420 | | |
|
FINRA filing fee
|
| | | | 2,300 | | |
|
Printing
|
| | | | 48,000 | | |
|
Legal fees and expenses
|
| | | | 142,483 | | |
|
Accounting fees and expenses
|
| | | | 54,000 | | |
|
Miscellaneous fees
|
| | | | 60,368 | | |
|
Total
|
| | | $ | 308,515 | | |
1 Year Addex Therapeutics Chart |
1 Month Addex Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions